Browsing by Subject "Small cell lung cancer"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Open Access
    Beta-catenin expression pattern in small cell lung cancer: correlation with clinical and evolutive features
    (Murcia : F. Hernández, 2001) Rodríguez-Salas, N.; Palacios, J.; Castro, J.de; Moreno, G.; González-Barón, M.; Gamallo, C.
    B-catenin expression in small cell lung carcinomas (SCLC) was investigated by immunohistochemical method using antibodies against B-catenin. 50 pre-treatment biopsies were examined and the relationship between B-catenin expression and the patients' relevant clinical characteristics, response to chemotherapy, time to relapse or progression, and overall survival, were analyzed. 0-catenin expression exhibited different intensity within each sample, predominantly localized in the cytoplasm, and no sample showed nuclear expression. There was cytoplasmic hyperexpression in 14 cases, hypoexpression in 15 cases, and normal expression in 21 cases. We did not find any association between B-catenin expression and clinical data. Our results show, however, correlation between Bcatenin cytoplasmic hyperexpression with a shorter time to progression (p=0.0437) as well as with a shorter overall survival @=0.0253). B-catenin hyperexpression could have prognostic significance in SCLC.
  • Thumbnail Image
    Publication
    Open Access
    NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2022) Lee, Jung Hee; Shin, Dong Hoon; Lee, Sang Yull; Park, Jun Young; Kim, So Young; Hwang, Chung Su; Lee, Hyun Jung; Na, Joo Young; Kim, Jee Yeon
    Neuroendocrine neoplasms (NENs) such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have characteristic histologies, but immunohistochemistry using neuroendocrine markers is still desirable to confirm diagnosis. CD56 is the most sensitive marker, but also stains various normal tissues and other tumors. Recently, we reported that nucleolar protein 4 (NOL4) is present in the blood of SCLC patients and found it was stained in the SCLC nuclei. In this study, we compared expressions of NOL4 and CD56, using 64 cases of SCLC, 18 cases of LCNEC, 6 cases of atypical carcinoid tumor, 7 cases of typical carcinoid tumor, 68 cases of lung adenocarcinoma, and 62 cases of lung squamous cell carcinoma. For primary lung NENs, sensitivity, specificity, positive predictive value (PPV) and negative predictive value of NOL4 were 77.5%, 95.8%, 93.2%, and 85.1%, respectively, while those of CD56 were 92.1%, 93.3%, 91.1%, and 94.1%. The specificity and PPV of NOL4 were higher than those of CD56, although the differences were not statistically significant. However, NOL4 retains its nuclear immunoreactivity in areas of crush artifact or necrosis. Furthermore, NOL4 was not expressed in adjacent normal tissues including bronchial cells and pneumocytes. Therefore, a combination of NOL4 staining with other cytoplasmic or membranous neuroendocrine markers might enhance diagnostic utility for SCLC and other NENs.
  • Thumbnail Image
    Publication
    Open Access
    Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China
    (F. Hernández y Juan F. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología, 2014) Xuan, Hong; Jingshu, Geng; Fang, Yang; Na, Li; Xiaolin, Sheng; Zhaoyang, Yang; Meng, Wang; Gongyan, Chen
    Studies have confirmed that protein overexpression or mutations of KIT are involved in growth and development of a variety of cancers. however, little is known about data of gene mutation and protein expression in small cell lung cancer (SCLC) patients from northeast China.The aim of study is to investigate gene mutation and protein expression in such patients with small cell lung cancer (SCLC) and analyse their clinical significance.The expression of c-Kit protein was analyzed by immunohistochemistry in 77 SCLC samples and 22 normal lung samples. KIT mutations were screened in exons 9, 11, 13, 14, 17 and 18 by DNA direct sequencing.The study showed that positive staining for c-Kit was observed in 28 of 77 SCLC patients . There was no correlations between expression of c-Kit and sex, ages, smoking status, stage. only 1 case was found to have known T801I mutation in exon 17. The median survival (13.9 months) of cases with c-Kit-positive was shorter than that (19.9 months)of cases with c-Kit-negative. The finding revealed that stages was identified as an independent predictive factor for SCLC patients.Our finding reveals that somatic mutation of KIT is rare in SCLC patients from the northeast China and there is no enough evidence comfirming KIT inhibitors for treatment in SCLC.